Evidence map›Paper›PMID 34358115›Full record

ArticlePharmaceuticals (Basel, Switzerland)2021

Small Molecule-Peptide Conjugates as Dimerization Inhibitors of

Alejandro Revuelto, Isabel López-Martín, Héctor de Lucio, Juan Carlos García-Soriano, Nicola Zanda, Sonia de Castro, Federico Gago, Antonio Jiménez-Ruiz, Sonsoles Velázquez, María-José Camarasa

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alejandro RevueltoInstituto de Química Médica (IQM-CSIC), E-28006 Madrid, Spain.ORCID 0000-0002-0226-040X
Isabel López-MartínInstituto de Química Médica (IQM-CSIC), E-28006 Madrid, Spain.
Héctor de LucioDepartamento de Biología de Sistemas, Universidad de Alcalá, E-28805 Alcalá de Henares, Spain.ORCID 0000-0002-9840-0779
Juan Carlos García-SorianoDepartamento de Biología de Sistemas, Universidad de Alcalá, E-28805 Alcalá de Henares, Spain.
Nicola ZandaInstituto de Química Médica (IQM-CSIC), E-28006 Madrid, Spain.ORCID 0000-0001-8593-9380
Sonia de CastroInstituto de Química Médica (IQM-CSIC), E-28006 Madrid, Spain.
Federico GagoUnidad Asociada al IQM-CSIC, Área de Farmacología, Departamento de Ciencias Biomédicas, Universidad de Alcalá, E-28805 Alcalá de Henares, Spain.ORCID 0000-0002-3071-4878
Antonio Jiménez-RuizDepartamento de Biología de Sistemas, Universidad de Alcalá, E-28805 Alcalá de Henares, Spain.ORCID 0000-0001-8238-3081
Sonsoles VelázquezInstituto de Química Médica (IQM-CSIC), E-28006 Madrid, Spain.ORCID 0000-0003-2209-1751
María-José CamarasaInstituto de Química Médica (IQM-CSIC), E-28006 Madrid, Spain.ORCID 0000-0002-4978-6468

Funding

Comunidad de Madrid PLATESA2-CM ref.S-2018/BAA-4370Consejo Superior de Investigaciones Científicas CSIC-PIE-201980E028Ministerio de Ciencia e Innovación PID2019-104070RB-C2
6 · The paper itself

Abstract

Trypanothione disulfide reductase (TryR) is an essential homodimeric enzyme of trypanosomatid parasites that has been validated as a drug target to fight human infections. Using peptides and peptidomimetics, we previously obtained proof of concept that disrupting protein-protein interactions at the dimer interface of

Indexed as

dimerization inhibitorsleishmaniasissmall molecule–peptide conjugatestrypanothione disulfide reductase

Identifiers

PMID34358115
PMCPMC8308777

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.